MTNB (Matinas BioPharma Holdings) Notes Receivable: $0.00 Mil (As of Mar. 2026)


MTNB Matinas BioPharma Holdings Inc MTNB
30 GF Score
Price $0.61
! 3 Warning Signs
View Full Analysis

What is Matinas BioPharma Holdings Notes Receivable?

Matinas BioPharma Holdings MTNB -7.83% 30 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates MTNB with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

Matinas BioPharma Holdings's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Matinas BioPharma Holdings Notes Receivable Related Terms

Matinas BioPharma Holdings Notes Receivable Historical Data

* Premium members only.

The historical data trend for Matinas BioPharma Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Matinas BioPharma Holdings Notes Receivable Chart

Matinas BioPharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Matinas BioPharma Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MTNB
30GF Score
Matinas BioPharma Holdings Inc MTNB
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Matinas BioPharma Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Matinas BioPharma Holdings (MTNB) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Matinas BioPharma Holdings and its competitors.
Is Matinas BioPharma Holdings' Notes Receivable too high?
Matinas BioPharma Holdings' current Notes Receivable is $0.00 Mil. Overall, Matinas BioPharma Holdings has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Matinas BioPharma Holdings' Notes Receivable compare to SXTP and ARTL?
Matinas BioPharma Holdings' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Matinas BioPharma Holdings and its competitors. Matinas BioPharma Holdings's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Matinas BioPharma Holdings stock overvalued right now?
Matinas BioPharma Holdings (MTNB) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Matinas BioPharma Holdings' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Matinas BioPharma Holdings (MTNB), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Matinas BioPharma Holdings Business Description

Address 1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
30GF Score

Get the complete analysis for MTNB

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.61
Price